Trials / Terminated
TerminatedNCT01195649
Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 11 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this prospective, observational, post-marketing study is to evaluate the patient characteristics, pre-treatment and treatment duration in Renal Cell Carcinoma (RCC) patients who are candidates for systematic therapy and in whom a decision to treat with Nexavar® has been made under real-life practice settings and approved reimbursement restriction in Taiwan. Therefore, the main objective of the study is to collect data on: Prescription pattern: to determine the factors affecting compliance and duration of treatment with special attention given to education status, demography, disease details, pre-treatment, concomitant medication and other baseline data Nexavar® treatment and efficacy data Adverse events using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY43-9006) | Patients under daily life treatment according to local drug information |
Timeline
- Start date
- 2010-12-13
- Primary completion
- 2012-06-08
- Completion
- 2012-08-31
- First posted
- 2010-09-06
- Last updated
- 2019-06-04
Source: ClinicalTrials.gov record NCT01195649. Inclusion in this directory is not an endorsement.